Cartalax clinical report: joint and spine symptoms in a 2005–2006 institute program
A. A. Veretenko, O. U. Raigorodsky · 2011 · Reports on clinical studies of Cytomax and Cytogen preparations. Cartalax section, PDF pages 104–107
Reported findings and study design
A brochure labels these results as Cartalax research, but repeats the cohort and outcome percentages under Sigumir. Read the numbers as claims in this report, with unresolved product attribution.
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Reported population | 33 treated and 31 controls; ages 45–78 | Study period October 2005–February 2006 |
| Knee symptoms | Pain/mobility improvement in 68.5% of cases | 10 treated knee patients listed; denominator/calculation unexplained |
| Spinal symptoms | Pain reduction in 53.7% of cases | 15 treated spine patients listed; denominator/calculation unexplained |
| X-ray findings | No substantial radiographic change | |
| Osteoporosis | Fewer fractures and shorter hospitalization claimed; no numerical values provided |
The repeated Sigumir cohort, inconsistent totals and missing control outcomes prevent treating these percentages as a verified Cartalax effect or counting the two brochure sections as independent trials.
Source for the extracted data ↗ · Checked 2026-10-31
Molekul summary of the linked publication. Educational information, not medical advice. Seek qualified healthcare help for medical conditions.
Methods, limitations & source review
Study limitations
- The same cohort and outcomes appear under Sigumir; product identity and cohort independence cannot be resolved from this brochure.
- Table sex totals do not reconcile with its diagnosis rows. Response percentages do not map to integer patient counts in the listed small subgroups.
- No comparator outcome values, allocation methods or between-group statistics are given. No radiographic improvement was demonstrated.
- Regimens differ between the introduction, methods and recommendations; they cannot establish a validated dose.
Publication counts are not counts of independent trials. Reviews, translations and reports sharing participants may overlap. Findings apply to the studied preparation, population and endpoints.
Document format: Institute report reproduced in a product brochure
Review depth: Complete Cartalax section and matching Sigumir table checked
Source access and review scope
Downloaded brochure; Cartalax PDF pages 104–107 inspected, including table on page 106. Sigumir page 53 repeats the same cohort table and outcome percentages. Table totals contain arithmetic discrepancies. Retained as a source record, not an independent clinical replication.
Recorded source-check date: 2026-10-31. This date does not imply a completed systematic review.
Source type: Commercial reproduction of institute clinical report; duplicated preparation attribution
Citation and original source
Original source: A. A. Veretenko, O. U. Raigorodsky. Cartalax clinical report: joint and spine symptoms in a 2005–2006 institute program Reports on clinical studies of Cytomax and Cytogen preparations. Cartalax section, PDF pages 104–107 2011.
Molekul research summary: https://molekul.io/research/cartalax-institute-report-2011. Cite the original publication for its findings and this page when referring to Molekul’s summary or evidence appraisal.
Bibliography entry